7-Jan-2026
Kuehn Law Encourages Investors of iRhythm Technologies, Inc. to Contact Law Firm
PRNewswire (Wed, 7-Jan 4:42 PM ET)
iRhythm Technologies to Present at the 44th Annual J.P. Morgan Healthcare Conference
Globe Newswire (Mon, 29-Dec 4:30 PM ET)
From Hype to P&L: Hospitals Now Buying AI That Pays
Globe Newswire (Mon, 8-Dec 1:18 PM ET)
PRNewswire (Fri, 5-Dec 2:25 PM ET)
Globe Newswire (Fri, 21-Nov 8:10 AM ET)
Business Wire (Tue, 11-Nov 4:15 PM ET)
Globe Newswire (Tue, 11-Nov 8:05 AM ET)
iRhythm Technologies to Participate in Upcoming Investor Conferences
Globe Newswire (Tue, 4-Nov 4:30 PM ET)
iRhythm Delivers Record Revenue Growth and Margin Expansion as Q3 Results Point to Scalable Strength
Market Chameleon (Fri, 31-Oct 7:23 AM ET)
iRhythm Technologies Announces Third Quarter 2025 Financial Results
Globe Newswire (Thu, 30-Oct 4:05 PM ET)
iRhythm Technologies Inc is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Its principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that it believes allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. Each Zio System combines an FDA-cleared and CE-marked, wire-free, patch-based, 14-day wearable biosensor that continuously records electrocardiogram (ECG) data with a proprietary, FDA-cleared, CE-marked cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.
Irhythm Technologies trades on the NASDAQ stock market under the symbol IRTC.
As of January 7, 2026, IRTC stock price climbed to $187.39 with 305,699 million shares trading.
IRTC has a beta of 0.54, meaning it tends to be less sensitive to market movements. IRTC has a correlation of 0.05 to the broad based SPY ETF.
IRTC has a market cap of $6.04 billion. This is considered a Mid Cap stock.
Last quarter Irhythm Technologies reported $193 million in Revenue and -$.06 earnings per share. This beat revenue expectation by $9 million and exceeded earnings estimates by $.25.
In the last 3 years, IRTC traded as high as $212.00 and as low as $55.92.
The top ETF exchange traded funds that IRTC belongs to (by Net Assets): VTI, IWM, VB, VBK, VXF.
IRTC has outperformed the market in the last year with a price return of +103.0% while the SPY ETF gained +17.0%. IRTC has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +6.6% and +5.0%, respectively, while the SPY returned +3.0% and +0.2%, respectively.
IRTC support price is $180.92 and resistance is $189.04 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IRTC shares will trade within this expected range on the day.
